Value analysis of magnetic resonance imaging in diagnosing prostate cancer capsular invasion

This study aimed to investigate the diagnostic utility of Magnetic Resonance Imaging (MRI) in detecting extracapsular extension (ECE) in prostate cancer (PCa). The data of 120 patients admitted to the hospital was retrieved and assessed. All patients underwent laparoscopic radical prostatectomy, and ECE status was determined by postoperative pathological examination. The results showed that 41 patients exhibited prostatic capsule invasion. Multiple logistic regression analysis identified Prostate-Specific Antigen (PSA) ≥10.4 ng/mL, biopsy Gleason score ≥7, clinical stage T2c, positive MRI findings, and Apparent Diffusion Coefficient (ADC) value < 0.75 × 10−3 mm2/s as significant risk factors for prostatic capsule invasion. The predictive model equation was Logit(P) = −1.325 + 0.469 × PSA ≥10.4 ng/mL + 0.865 × biopsy Gleason score ≥7 + 1.743 × positive MRI findings + 1.495 × ADC value < 0.75 × 10−3 mm2/s. The receiver operating characteristic (ROC) curve yielded an area under the curve (AUC) of 0.769 (95% Confidence Interval (CI): 0.681–0.856, p < 0.001). In conclusion, these results indicate that integrating MRI with clinical risk factors in the predictive model demonstrates robust performance in identifying prostatic capsule invasion, demonstrating promising ability to enhance diagnostic and therapeutic strategies for PCa management.

Magnetic resonance imaging; Prostate cancer; Extra-capsular extension; Diagnosis

[1] Yuk HD, Byun SS, Hong SK, Lee H. The tumor volume after radical prostatectomy and its clinical impact on the prognosis of patients with localized prostate cancer. Scientific Reports. 2022; 12: 6003.

[2] Wang JG, Huang BT, Huang L, Zhang X, He PP, Chen JB. Prediction of extracapsular extension in prostate cancer using the Likert scale combined with clinical and pathological parameters. Frontiers in Oncology. 2023; 13: 1229552.

[3] Shiradkar R. Editorial for “multiparametric MRI-based peritumoral radiomics for preoperative prediction of the presence of extracapsular extension with prostate cancer”. Journal of Magnetic Resonance Imaging. 2021; 54: 1231–1232.

[4] He D, Wang X, Fu C, Wei X, Bao J, Ji X, et al. MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins. Cancer Imaging. 2021; 21: 46.

[5] Merder E, Ariman A, Altunrende F. A modified partin table to better predict extracapsular extension in clinically localized prostate cancer. Urology Journal. 2021; 18: 74–80.

[6] Guerra A, Alves FC, Maes K, Joniau S, Cassis J, Maio R, et al. Early biomarkers of extracapsular extension of prostate cancer using MRI-derived semantic features. Cancer Imaging. 2022; 22: 74.

[7] Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Lee K, et al. Validation of user-friendly models predicting extracapsular extension in prostate cancer patients. Asian Journal of Urology. 2023; 10: 81–88.

[8] Kang Z, Margolis DJ, Wang S, Li Q, Song J, Wang L. Management strategy for prostate imaging reporting and data system category 3 lesions. Current Urology Reports. 2023; 24: 561–570.

[9] Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Network Open. 2022; 5: e222246.

[10] Cybulski AJ, Catania M, Brancato S, Cogo N, di Paola V, Pozzi Mucelli R, et al. Added value of MRI tractography of peri-prostatic nerve plexus to conventional T2-WI in detection of extra-capsular extension of prostatic cancer. Radiologia Medica. 2019; 124: 946–954.

[11] Zhu Z, Zhu Y, Xiao Y, Hu S. Indications for nerve-sparing surgery for radical prostatectomy: results from a single-center study. Frontiers in Oncology. 2022; 12: 896033.

[12] Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. European Urology Oncology. 2021; 4: 868–876.

[13] Scialpi M, Martorana E, Scialpi P, Scalera GB, Belatti E, Aisa MC, et al. S-PI-RADS and PI-RRADS for biparametric MRI in the detection of prostate cancer and post-treatment local recurrence. Anticancer Research. 2023; 43: 297–303.

[14] Yilmaz EC, Shih JH, Belue MJ, Harmon SA, Phelps TE, Garcia C, et al. Prospective evaluation of PI-RADS version 2.1 for prostate cancer detection and investigation of multiparametric MRI-derived markers. Radiology. 2023; 307: e221309.